Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOPAS: ustekinumab in active ankylosing spondylitis
2011-000844-56Phase 2Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Jun 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ustekinumab in ankylosing spondylitis (AS), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: ASAS40 response at week 24. Started Jun 2011; status: completed.
02
Drugs
ustekinumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on 2011-000844-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000844-56.